CAMYO-01 / myNEO Therap - LARVOL DELTA

CAMYO-01: colorectal cancer-specific camyotypes formulated into an mRNA vaccine (WVCE 2024) - "Aberrant shared translation events in cancer cells lead to novel dark tumor shared antigensShown to be highly presented, highly immunogenic, and capable of inducing tumor regressionIn parallel to the lead CAMYO program in CRC, other indications have shown a similar set of camyotope targets, leading to the buildout of a large antigen library across tumor indications"

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CAMYO-01: an off-the-shelf MSS-CRC vaccine targeting camyotopes, a novel and unique class of shared antigen targets derived from the dark genome (CIMT 2024) - "Indeed, the coverage achieved by camyoRNAs significantly surpasses that of other antigen-based off-the-shelf approaches. We are now initiating our lead program CAMYO-01, a camyotope-encoded mRNA-LNP vaccine, which will enter the clinic in 2025 as a novel therapeutic strategy for CRC patients."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CAMYO-01: an off-the-shelf MSS-CRC vaccine targeting camyotopes, a novel and unique class of shared antigen targets derived from the dark genome (CIMT 2024) - "Indeed, the coverage achieved by camyoRNAs significantly surpasses that of other antigen-based off-the-shelf approaches. We are now initiating our lead program CAMYO-01, a camyotope-encoded mRNA-LNP vaccine, which will enter the clinic in 2025 as a novel therapeutic strategy for CRC patients."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor